Obesity is a major risk factor for NASH, and metabolic interventions such as bariatric surgery (BS) and glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) have been explored for their impact on liver‐related outcomes. This evidence concerns the gene GCG and obesity disorder.